EUVC #286 Julia Hawkins, GP at LocalGlobe & Phoenix Court on building a healthcare franchise in a generalist fund

5 Mar 2024 · 1 h 5 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Notes: EUVC Episode #286 - Julia Hawkins, GP at LocalGlobe & Phoenix Court

Episode Overview

  • Title: EUVC #286 Julia Hawkins, GP at LocalGlobe & Phoenix Court on building a healthcare franchise in a generalist fund
  • Hosts: Andreas Munk Holm and David Cruz e Silva
  • Guest: Julia Hawkins, General Partner at Phoenix Court and LocalGlobe
  • Description: Julia discusses her career journey, experiences in venture capital (VC), the healthcare sector, and the unique approach of LocalGlobe in building a healthcare franchise within a generalist fund.

Key Topics Discussed

  1. Introduction to Julia Hawkins
  2. Julia is a General Partner at Phoenix Court, managing a $1.5bn AUM multi-stage tech investor.
  3. She focuses on health and hard tech, with notable investments in AccuRx, Oxford Nanopore, Vaccitech, Spore Bio, and Early Health.
  4. LocalGlobe primarily invests in pre-seed and seed stages with a portfolio of over 200 companies.
  1. Defining Multi-stage Investing
  2. Multi-stage vs. Live-stage Investors: Julia elaborates on the significance of multi-stage funds which support founders from pre-seed through to IPO.
  3. Phoenix Court has various funds to cater to different stages, including LocalGlobe (pre-seed), Latitude (breakout), and Solar (pre-IPO).
  1. Personal Journey into Venture Capital
  2. Julia's background is shaped by her mother's resilience and her experiences attending international schools, which fostered her appreciation for individual narratives.
  3. A pivotal moment was her rejection from the London School of Economics (LSE) and her subsequent proactive approach to gain admission, highlighting determination and the importance of showing up.
  1. The Impact of Personal Experiences on Career
  2. Julia discusses the influence of her daughter's rare genetic condition on her understanding of healthcare and her investment perspective.
  3. Her experience navigating healthcare systems led her to realize the potential for technology to improve healthcare delivery.
  1. The Future of Hard Tech in Europe
  2. Julia shares her belief that hard tech will become a significant area of growth in Europe, countering views that downplay its potential.
  3. She provides examples of companies like Oxford Nanopore, Automata, and CoMind, showcasing successful intersections of deep tech and business viability.
  1. Building Relationships and Community in Healthcare
  2. Julia highlights the importance of community engagement during the COVID-19 pandemic as a foundation for LocalGlobe’s healthcare investments.
  3. Partnerships with local healthcare practitioners and institutions have proven essential for navigating the healthcare landscape effectively.
  1. Mentorship and Diversity in Venture Capital
  2. Julia emphasizes the role of mentorship, particularly for women in VC, and how diverse teams lead to better decision-making.
  3. Despite challenges in the industry, she advocates for the necessity of maintaining diversity and inclusivity within venture capital.
  1. Advice for Emerging VCs
  2. Julia shares insights on developing a distinctive edge, maintaining strong communication with founders, and building relationships with follow-on investors.
  3. She stresses the importance of clear investment memos and tracking investments closely.
  1. Key Learnings from Her Experiences
  2. Values: Articulating values is vital for decision-making.
  3. Turning Challenges into Opportunities: Adversities can provide crucial lessons.
  4. Conviction in Investments: Bold, non-consensus decisions can lead to substantial outcomes.

Conclusion Julia Hawkins concludes by reflecting on the venture capital ecosystem's need for greater social responsibility and the importance of impacting local communities positively. She expresses a commitment to align her investment practices with these ideals through initiatives like Phoenix Court Works, which supports social causes using a percentage of management profits.

Key Quotes

  • “I think the venture community has broadly failed to increase living standards.”
  • “Your biggest challenges will become your most important teachers.”
  • “You can be yourself and still win.”

Additional Information

  • For full insights, visit the EUVC podcast website at [eu.vc](https://eu.vc).
  • The episode encourages listeners to engage with the podcast and share their feedback, fostering a community of knowledge sharing within the European VC landscape.

Related Links

  • Julia Hawkins LinkedIn: [Julia Hawkins](https://www.linkedin.com/in/juliahawkins01/)
  • LocalGlobe Website: [LocalGlobe](https://localglobe.vc/)

---

These notes encapsulate the discussions and key insights from the podcast episode with Julia Hawkins, providing a comprehensive overview for readers interested in venture capital, healthcare innovation, and the European startup ecosystem.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:00Hi, everybody, and welcome to the European VC podcast. I am Andreas and not with me today is David because he's unfortunately ill. So today we have with us Julia Hawkins. Julia is a general partner at Phoenix Court, a 1.5 billion AUM EMEA multi-stage tech investor backing the most ambitious founders on their journey from seed through to the public markets and beyond over the last two decades. Local Globe is the pre-seed and seed fund investing out of Phoenix Court's Fund 12 with an established portfolio of over 200 companies with notable investments including AtBay, Motorway, Sego and Improbable.

0:43At Phoenix Court, Julia focuses on health and heart tech and lead investments in AcuRx, Oxford Nanopore, Vacutech and more recently Sport Bio and Early Health. If you're listening in and love our show, do drop us a review and follow the pod and subscribe at EU.BC.

1:26European response. Europe is a story of new beginnings. New beginnings. Let's start acting. Acting. This episode is brought to you in partnership with Zero 100 Conferences, which organises networking events connecting LPs and GPs in private equity and venture capital firms across Europe. Their upcoming event, the Zero 100 Conference DAG, will take place on February the 28th to the 29th, 2024, at the Hotel Savoy in Vienna. Attendees will include major LPs and GPs like Atomico, AXA Venture Partners, Early Bird, Erst Group, Dawn Capital, Unica, and many other LPs and GPs. Save the date, February the 28th to the 29th, 2024 at Hotel Savoy in Vienna.

2:15Join us in Vienna. This show is not investment advice and the hosts of this episode may be invested in the funds and companies featured. So, Julia, we recently had George with us on the podcast as well. And we asked him a bit about how, if he could help us clear up Phoenix, Core, Local, Global, how does that all play together? What's what? and I will just, instead of diving into that here, I'll just tell our audience, go listen to that episode. It's a great one as well. And then you can get the full backdrop there. But Julia, we had a small conversation about multi-stage tech investor versus live stage tech investor.

3:03And I would love to just ask you to kind of just set the stage and make sure that everyone understands what you mean with multi-stage tech investors slash live stage investor, because that is quite significant part of Local Globe and Phoenix Court. Absolutely. And hi, Andreas, and thank you for having me on the show. But yeah, to answer your question, I mean, we have different funds that enable us to partner with the founder all the way from pre-seed up to IPO and beyond. And so Local Globe is our pre-seed and seed stage fund. Latitude is our breakout fund. And then solar is our pre-IPO fund. And we also have Basecamp, which is a fund-to-fund program.

3:49And yes, so this really enables us to partner with founders from zero to IPO. And to everyone in the audience, as you can probably figure out, we're on a local globe tour, Phoenix Court tour, trying to get around all the many different facets around what Local Globe and Phoenix Court had grown to be. So watch out for more episodes with the Local Globe team. So, Julia, now after I've asked you to give us that small intro, I want to ask you to tell us about your story about how you got into venture. I guess by explaining my journey into venture, I thought that I would highlight three people and pivotal experiences that I think have really shaped me.

4:38I think the first one I have to call out is my mom. So my mom comes from a very, very small town in Sweden. She is the 11th sibling out of 12. And when her dad died, when she was nine years old, she basically got given a scholarship to study at university. When I was eight years old, she got a job at EFTA, and we moved to Geneva. So me, my older sister, my mom moved to Geneva and I started an international school. And I would say that this is a really pivotal experience for me because attending the international school really enabled me to see the individual. So my mom's determination gave me this education that from a very young age enabled me to see the individual in front of me.

5:28I was friends with Saddam Hussein's niece and grew up having people like that as being friends. So that's my first experience. The second one I want to call out is the admissions officer at LSE. I had decided that I really wanted to study government at LSE. I actually didn't get in when I applied. And so what I did was I got on a plane. I went and knocked on the physical door of the admissions office. And I said, hey, I really want to go here. I feel very aligned with the values of LSE. I think that I could really belong here. Is there anything that you could do for me? And the woman just looked at me and she said, well, have you considered social policy in government.

6:25And I said, I haven't, but that sounds amazing. And so I also learned, I guess, also quite early on that a no can turn into a yes. It's important to show up. And I learned so much from my time at LSE. And it also obviously led me to finance because my first job was at Goldman. But she was really pivotal for me. You said you believe that LSE had, you were so aligned with the values. I need to ask you because LSE to me, I don't know what the LSE values, but I definitely know the value of LSE and an LSE degree. Tell me a bit about, you know, that reflection on their values that make you want to go to LSE specifically.

7:16And also after that, I'd love to ask you to think about, how I should have put it now, you're an LSE graduate and so are many of your colleagues in the venture industry. And if they're not from LSE, they're oftentimes from another very high pedigree school. So let's talk a bit about diversity of the venture landscape as well as part of this conversation. Yeah, sure. I guess when I thought about the values of LSE, there were some, I guess, prominent social thinkers that had played a role. And even in terms of the foundation of the welfare state, you know, LSE had been a prominent figure in that.

7:57And I think that's what really resonated with me. My granddad, so my dad's dad, was a social worker. He was also hugely influential on my life. And I think I grew up with these very liberal and I guess more liberal ideals and with this idea of, you know, welfare state and redistribution of wealth being important. And so I felt that the LSE was the institution that was most aligned with me on that basis. That was, I guess, one of the questions that you had. The second one, I think, in terms of pedigree of institution, and yes, and I think this is one of the things that I really think about and why it's really important to look at the individual as opposed to necessarily where they have graduated from.

8:48And really try to understand what has the person had to endure and overcome to get to where they are today. and don't look so much at the labels, but really look at the circumstances that led the person to where they are today. You said something that I have to ask you about, which is redistribution of wealth and you aligning with that mindset. I'm a Danish person. I sometimes call myself the socialist venture capitalist because I very much believe in redistribution, right? And I think your mom, at least coming from Sweden, would likely also ascribe to that. So I'd love to ask, having been in venture now for so many years and having been so hugely successful, in the end, both very finance, the finance world, but at the same time also some would call us the hippies of the finance industry.

9:48How have you managed to stick to those ideals? Because it is a world typically not governed by people that believe in redistribution. Yes. Andreas, we're jumping ahead because some of these insights are like in my, like my, the non-conventional insights about venture capital. I think you're hitting the nail on the head. I think that, you know, if I am critical of venture capital, it has not achieved the kind of redistribution of wealth that we think could be possible. If I look at Summerstown, and I'm going to talk a little bit about that later on in our chat, you know, where we are based in Summerstown, which is the poorest community in Camden, it is the highest proportion of child poverty.

10:44For us, it was really important to try to surpass what is actually being already done by the government. And we set up a foundation, which basically makes donations to local organizations. And it's based on different themes. So health and well-being, education and inclusion, climate and the environment. and we essentially have 10 % of profits from a management company, 2 % of carry across all of our funds. They go into this foundation and we've partnered with, at this point in time, I think over 30 organizations. My big question is like, how do we enable Phoenix Court Works at scale? Like that's, we've made a little bit of a dent.

11:30We've scratched the surface, but yeah, I think for me, that's a really big question. And how does this, you asked me how I've remained true to that. I mean, I think that's a really good question. But for me, I just think that it's in my blood. Like it's in my, it's just what I believe. Absolutely. Yeah. No, I get that. And I'm much early in my career. But I'm definitely seeing that these discussions sometimes, you know, in the wee hours of the night, you have them with your peers in the industry. And redistribution is not typically something that you find a common peer thinking about. But now let's get back on track and I'll ask you to pick up on your third key person of influence in your life.

12:15Yes. So I have to call out Saul because he's played a huge role in my journey into venture. For the audience, Saul is, of course, Saul Klein, one of the founders. Right. Saul Klein is the co-founder of Local Globe, Latitude, Solar. He's the co-founder of Phoenix Court alongside his dad, Robin. But actually, the person who introduced me to tech was not Saul. It was actually Danny Reimer. Danny Reimer is, of course, Mr. Index. At Index, he had led an investment into Last.fm. Tech was becoming a thing when I was at Goldman. And so I guess I started using Last.fm and thought, oh, my God, this is the most amazing thing that I had experienced on the Internet, like streaming music, being recommended music based on what you had previously listened to.

13:08I was like, my mind is blown. I want to be part of this. And so he was kind enough to make an intro to Stefan Glanzer, and I met the rest of the Last.fm team. I joined them a couple of weeks later and was part of this phenomenal European breakout journey in music. And it really helped me and gave me an understanding of what it means to work for a venture-backed company. So I met Saul the first time when I was at Last.fm, but he became even more important to me when I was at Universal Music because I joined Universal Music after Last.fm. And the reason I joined Universal was because I really wanted to see if I can have an impact in terms of how labels interact with startups.

13:55Last.fm had had a phenomenal exit, but I didn't think that it had reached its full potential. And one of the reasons was because they didn't interact with the labels. And so I thought that creating a corporate venture arm could be one way to solve this relationship challenge. And so I was part of the team that set that up. And I was leading investments from Europe. Sol basically made me see that this was not really the way to have the kind of impact. and if I wanted to have the impact, the kind of impact that venture, that it was possible to have through venture, then I needed to be inside a fund.

14:38Yeah, it was really pivotal. He really helped me and then a couple of months later, Local Globe was like basically put out a tweet saying, we're hiring, apply. And so I did just that and there were lots of people who helped me on that journey. Obviously, I mean, without the experience at Universal Music, I wouldn't have gotten my foot in the door. The Kauffman Fellows were really transformational for me. The founders that I'd backed, I mean, Rafe at SoFar Sounds, Roland at Roley. There were co-investors like Daniel Waterhouse at Boulderton. There were LPs like Joanna at Chicago. Like all of these were, really helped me make it to LocalGlobe.

15:28But I would say that my first true believer within Venture was Saul. I guess I'll always be really grateful to him and his dad for enabling me to be part of this platform. All right. So now I'll go to a different part, which is asking you about a pivotal moment in your life. And I love your answer to this. So let's get into it. I guess a pivotal moment in my life was when my daughter was born. She was actually really, really poorly. And she was diagnosed with a rare genetic condition when she was eight months old. She's now turning nine and she's doing well. But this experience of navigating various health systems to get to her diagnosis, to identify academics who were doing research on her condition, reaching out to them, understanding, I mean, understanding what her condition even meant, like reading high school biology books to understand the functions of a ribosome, even creating patient communities, setting up a charity, really understanding all of the aspects of developing a drug for a rare genetic condition, setting up a registry.

16:47So for health data, as well as samples, this whole experience really shaped me. It was mind boggling that it was so difficult. Every single step was so difficult. And I guess on the, I guess on the macro as an investor side, I hadn't, I hadn't appreciated just how big an opportunity it was. You know, in the UK, it's something like 11 % of GDP that's spent on healthcare in the US is 20%, by the way, with similar outcomes. And I just felt as someone with experience in technology, that technology can help improve whether it's access, whether it's coordination, whether it's drug development, every single part of healthcare could be improved.

17:34And so I guess it shaped me as an investor because it opened my eyes to a vertical that I knew absolutely nothing about. It showed me a blueprint for how to think thematically as an investor, so that in which I can take forward into into new themes that I'm exploring. And I guess on a personal level, I turned my experience into mission. And basically, I just, yeah, I just set out to make really impactful investments. And yeah, I think this was definitely one of the most pivotal experiences so far. Yeah, and I think it shows so much about how a venture can be really a force for good. And I have all the respect in the world for you to wielding it, to be excited about that.

18:26But now let's go into the Take a Stand section. Take a start.

18:41Julia, I'll ask you to comment by this quote by Stefan Helgesen from Creandum, that hard tech is going to be the next big thing in Europe. Yeah, so he does not think that. But I have to start by saying that I absolutely love Creandum. I have huge respect for the fund, not only because I'm Swedish, but also because they are phenomenal investors. I sit on a board with Johan Brenner and he's amazing. and the entire team at Creandum I love. So I say this with huge respect. But Staffan basically says that he doesn't think that deep tech is Europe's next big thing. And he says for a couple of reasons.

19:20He says the number of valuable companies are few. The main point of his argument is actually around nutty professors. And he says that they often don't have the desire or ability to sell their inventions. and he also may not have the determination that we see in other types of founders. He also says that so much about innovation is about design and user experience. And so he doesn't think that this is the next big thing. I happen to think that it is. And so I guess I just wanted to take a stance on what Stefan said. So I don't think anyone disagrees with the macro arguments in terms of talent, spin outs.

20:04It being a large category, actually emerging pools of capital coming in, in particular governments really getting behind deep tech and the importance of deep tech. But Staffan's main criticism is about this concept of the nutty professor and that they're not able to build these big businesses. And so I guess I just wanted to call out a couple of examples of founders that I think exemplify or companies that I think exemplify being able to marry the nutty professor with becoming big businesses.

20:39We should get into that as a discussion part, because I have definitely been in this space as well and can see arguments in both directions. So I'm very curious to dive into this. But first, let's hear your three examples and then let's dive into it. Yes, sure. So Oxford Nanopore, which is a next generation sequencing company, it took the company 16 years to get from lab to IPO listing. And Oxford Nanopore was spun out from the chemistry lab in Oxford. So it was the nutty professor alongside Gordon Sangera, who's the CEO, and Spike Wilcox, who's the CBO. It then took them about 12 years, 12 years to get to product market fit with a Minion, which was the first portable commercial sequencing device.

21:30And I think that was only started to be available in 2015. the long-term prospects is that as biology, data, and software are all starting to come together, this has huge potential to be a very, very valuable company, maybe even as big as ARM. And I think what my takeaway was that, yes, there was a nutty professor, but there was also a team around. There was Gordon Sanguera, who's a phenomenal CEO. By the time the company went public, there were also people like John, who's a CFO, Zoe, who was phenomenal in both, yeah, in corporate development. And these are all like world-class operators, and they were all swinging for the fences, which is a term that obviously Creandum know as well and talk a lot about.

22:27So that's my first example. My second example is Automata. So this is a lab automation company. When we talk about the impact of this company during COVID, they basically helped one trust or one hospital get from 1 ,000 tests per day to 100 ,000 tests per day. And Mustafa, who's the CEO and founder, I mean, he's an architect. He's not a nutty professor. But he, after his undergrad, he actually studied alongside Saha Hadid and then had this insight about using robotics and automation to enable other industries outside of architecture. He founded Automata, and now they are phenomenally impactful in the space of life science.

23:18And then my third example is CoMind. And this is also an example of a founder who I think is just amazing. The company is focusing on non-invasive brain monitoring. James, when we met him, he was only 17. He comes from a really small town in Harrogate in Yorkshire. and he started programming when he was 13 years old. He's completely self-taught. He taught himself TensorFlow and was working on autonomous vehicles before he basically became very interested in how the brain works. And his interest there was because a family member sadly committed suicide. And so he just became obsessed with understanding how the brain works.

24:06The unique thing about James is his ability to learn. This is what we have seen time and time again, his ability to learn. And why, you know, now, obviously, he didn't go to university. He became a TEAL fellow, which became quite important for him in terms of recognition. But the first product is a medical device, which enables triage and monitor traumatic brain injury. and this impacts millions globally. So this could become one of the most impactful European companies and it's led by a founder who didn't even go to university. What I think is that these founders, they are really looking for investors who understand them and I don't want to be too much on the hard tech high horse because I also know that there is definitely some pushback And it goes without saying that software and soft tech companies will continue to also be hugely important.

25:08But this is as a category requires slightly different thinking, you know, long term capital, deep science expertise, helping companies get to technology market fit as opposed to product market fit. I mean, that comes to but technology market fit initially. And so I think that the companies, the most valuable companies over the next 20 years will be science-based. They will be multidisciplinary. They could be Amin from SporeBio. It could be DJ and Thomas from Erdy Health. And I think this is the next big challenge for us as investors. Now, let me ask you about the Europe part, because some see Europe as being particularly well established or positioned to capture this hard tech opportunity vis-a -vis the U.S.

26:01What's your take on that? And because oftentimes the argument goes along the lines of very strong research universities, very big base of industrial companies here, all those things. Do you think that that is why? Or do you think it's more about, well, this is the next place, the next vertical, so to say, where venture will have its impact. And it's not connected to Europe as such. It's more just where tech is. I think it's a really good question. I need to look at the numbers from Deal Room. I think that if you look globally, it could well be that we have already surpassed the 50-50 point where hard tech converges or basically meets the same amount of venture capital being invested into it as a segment compared to soft tech or everything else.

26:57And that obviously depends on the definition of hard tech. If you look at just deep tech, I think it's definitely you can say that it's as a segment has been very resilient. And in particular, over the last 12 to 24 months, where it's even surpassed segments, like, I think, if you look at the last deal room report on deep tech, it showed that it's now even I mean, it's bigger than than energy, even than health and fintech. And so it's a very resilient segment. But I do think that the challenge and the US and has been more successful at this is effectively at commercializing. So helping these technologies get to technology market fit, as well as then to product market fit.

27:46And I think that's what I mean by the challenge that's now before us from when it comes to, yeah, when it comes to this segment. And when you talk about technology market fitness, something for us to consider, which you don't have to in the same way in software tech. You're also hinting at least at the existence of another playbook or slightly or rather differentiated playbook for hardware versus software. I'd love to ask you, how do you see that playbook? I don't want to ask you how it differs because that's too big of a question, but rather how do you see the traditional VCs being able to kind of get a grasp around this part?

28:40Because it's not a simple exercise from going from pure SaaS to all of a sudden doing deep tech and hard tech. Yeah. Does it require new investors or can it be taught slash learned? I think there's probably a combination of both. And I do think that there is a way to get help or advice in different sectors or different technologies that can help investors really understand whether something is truly breakthrough and which markets this could be applied to. and we can talk a little bit about that a little bit later when I can share some of the learnings from how we built our healthcare network. But I think that's absolutely right.

29:27So for example, if I think about Automata, one of the biggest challenges for them has been to find product market fit. And obviously now they have it, but it took them some time. And one of their biggest learnings was they wanted to actually, they should have gotten out to different customers earlier on And maybe they wouldn't even have developed the first robotic arm because it actually didn't end up being, wasn't useful to their current customer. And so I think there is a, and by the way, I think tech investors do this really well. Like we're constantly asking questions around customers. And so I think that there is a natural role for the current cohort of investors.

30:15But I do think it has to be supplemented by experts or by other individuals that can go deep into some of these scientific areas and then build out advisory boards to support or community of individuals who can support. And I think we've got, we had a really good playbook for how we did that in health. And so I'm excited about doing that in hard tech too. So now let's, I don't know if this is stretching it, but get into the playbook of doing it in health, because I want to get into our deep dive section. We're going to talk about building a healthcare franchise in a generalist fund. And with that, I really just want to kick it to you, Julia, and take us into it.

31:04Because that's, of course, exactly what you've done at LocalGlobe. Yes, well, absolutely. And thank you. And I do think this does actually help us in the discussion around deep tech as well. When we started in 2018, which was when I joined, I guess it's very safe to say that we already had an established and very good brand in LocalGlobe. We had made some investments in healthcare already. Companies like Echo, ULife, MyHeritage, Zebra were all existing investments, but I wouldn't say there wasn't a real focus around healthcare. It's obviously a huge and complex market. There are many companies who haven't made it.

31:47There are many different types of investors. Where we are now is that we have a portfolio of companies. It includes some breakout companies like Acarix, Oxford Nanopore, Vaxitech, SORD, Cosign Therapeutics, CoMind, as we've spoken about, Automata, and then more recently, Care Hero, Apien. Panacchia and some women's health companies like Vera and Hirtility. And so I guess what I wanted to share was like looking back, how did we go about doing this? The TLDR is that, and the truth is that we actually didn't really know when we started. It wasn't strategic, but I guess I just wanted to highlight some of the things that we did and what we learned.

Read the full transcript

32:34I guess the first thing to say is that, you know, it's really important where we're based. So Summerstown, and I'll tell you a little bit about it here. We spoke about it earlier, but obviously, I mean, I think that it's an edge in the investments that we make. It's the poorest community in Camden, lowest mean household income, highest proportion of child poverty. If you live here, you are going to live 15 years less than if you live 15 minutes up the road in Belsize Park. I guess it goes without saying as well, like the kinds of institutions that are on our doorstep are phenomenal. So there is the Crick, which is just behind me.

33:15There is DeepMind, which is also just around the corner. We're about a 10 minute walk from Great Ormond Street. There is UCLH. There's Royal Free, which are leading hospitals in London, in terms of pharma companies, Merck, GSK, Nova Nordisk have moved in like literally here in this part of town. And so I think that we're at the epicenter of healthcare. But then as a location, it has also opened our eyes to what it actually means to deliver healthcare to communities. And so what happened during the pandemic, we started working really closely with our local primary school to deliver testing. We tried to understand what the reluctance and take up to vaccinations and testing was.

34:06We explored shared appointments. So we partnered with a researcher, Kamalini Ramdas, who's at LBS, who's like a world leader in shared appointments in terms of delivering information to cohorts of individuals. And I think we learned so much. And that's because we are based in Somerstown. And so, yeah, I mean, the importance of clear communication in healthcare is paramount. Can I ask you, just because you're saying, we did, we did, we did. We as in Local Globe. Yeah. As in Local Globe's team focused on healthcare. I think to many, in our audience, that's a bit baffling. This does not sound like the normal practice of a VC, right?

34:58Is this something that has been particular to your healthcare practice? I was about to say healthcare arm, vertical, or is that very much how you work? So when you do hardware, as an example, and now starting, you know, write that playbook. Do you think that you need to build the same type of dynamics there or will that be another? I think that COVID was a unique experience. And I do think that the relationships that we built during COVID in this non-transactional way really laid the groundwork for some of the relationships that have become really important for us when we then start to make investments and working with companies.

35:47But I would completely agree with you. And it's so funny because it mimics a bit what I see with emerging managers that are great in a vertical, right? Because they almost have the same story as what you just described. Yours was just incepted inside of a firm. But it's like I was in robotics. I'd been here for 10 years as a professor. I'd been at Universal Robots. Then I was at Mir. Then I helped with blah, blah, blah, blah, blah, right? And then kind of that one-man team or two, three-person team have that whole story that kind of mimics what you're saying, but it's just a story about their small first-time fund.

36:27And that explains why. And many emerging managers are incredibly exciting, right? So I'd be curious to ask you, how do you think about it now when you're then building out the deep tech or the hard tech? So I think there are some clear learnings that we have taken. And I think, obviously, the importance of establishing nodes so people and community have been really important for us. And I think that will be the same in hard tech. They won't be the same. There may be some overlap, but there may not be. So, for example, someone who's been really important for us in health care has been Jane, Dr.

37:12Jane Myatt. She's a co-founder of a GP practice here in Camden. She's a primary care doctor. And we started donating money from Phoenix Court Works to her practice so that she could spend one day a week developing these new methods of social prescribing. So social prescribing is like, you know, come to us to this and do this cooking class with us. Try not to take antidepressants, come do walks with us. Anyway, there are these new ways of delivering health care. And so we have a very deep relationship with her. And I would just say that she's also instrumental. She's also wants to know about she loves Acurex, by the way.

37:54But when we're looking at new investments, I'm always like, Jane, how do you think about this? How would this help you? And she's a, in addition to obviously doing the other DD work that you would do for any investment, we also have our own network of individuals who can support us. So that's how we think about it. And there are others. Obviously, the amazing people at the Crick, there is Parker Moss, who is ex-Genomics England, now ex-Sciencia. He's been with us from day zero. So Lord Pryor, the woman who runs now NHS London, Caroline Clark, Ektar Raja. These are names, I mean, they're just names, but they're also people who are like on the end of a phone call when we are thinking about making new investments or when we're working with companies and who can provide links into the system.

38:52And I think that's just, I mean, we have found that leaning into regulation and policy has been also a superpower. Some funds shy away from that. We have found it to be really important. Saul is obviously, he's a non-exec director on DSIT, which is the Department for Science, Innovation and Technology. like that's been it's been it's been really important for us to have those links with regulation and policy and community and then I would also just say that yes I mean maybe you can be slightly more strategic on this point but at the same time like we held our first community event when we were still based in Tile Yard which is up York Way I mean it's a it's on an industrial estate.

39:43It's not fancy at all. There were 10 people who came. It was about AI and pathology. And it was just something that I had spoken to Parker Moss about. He helped us get a speaker from Genomics England. I called an author of a Wired article who had written something about AI and pathology. And I said, hey, we're doing this event. Do you think you could come and share a little bit about your research? And he said, yes, we didn't. Yeah, we started somewhere. We just started. And then from there, you can become more strategic. You learn more about the themes like within healthcare that you wanted to go deeper on.

40:20And then you build communities around that. Emerging managers have been very important. You know, David, who set up Voyagers, who's got this whole community around healthcare. Chris, who's done Atria, Jamie, Creator Fund, like is he at outside like all of these they they and I know you have a specific question on on emerging managers and I think they play such an important role in particular when it comes to sourcing but also co-investing and so yeah and then now there are now we also have health focused LPs and I think that's going to be really important to ensure that your LPs understand and empathize with some of the peculiarities of the investments that you're making.

41:05And so I think that will be one of the things that we spend time on next. You mentioned Creator Fund. Patrick, as an example, also Ramsey from No Label, both close friends of ours. Great firms. Could you tell me a bit about how you think about the intertwining of the emerging managers that you bank with your own active investing in local group? On the one hand, we have Basecamp, which is a fund-to-fund program, which is an angel investor into emerging managers. But I would say that, I mean, I think that emerging managers, for me, they form just a really important part of the relationships that I really value.

41:56I've co-invested with Jamie and Creator Fund and APN. Jamie brought that to us. The same with Ramsey. Ramsey brought Spore Bio to us. and it was phenomenal to be able to get to know those founders and then be able to work together and backing those founders. So I think sourcing is obviously critical. Yeah, and I think there are obviously certain ways in which you determine which of the founders or which of the emerging managers that you spend time with. And I think it's just the same way that you build conviction in anything. You need to spend time together. You need to understand how they think, even like thinking like consistent updates as well and clarity of thought.

42:41I would say that both Ramsey and Jamie do really, really well here as well as David from Voyagers. And then when there is, yeah, when there is obviously a connection and you want to, yeah, you want to understand which of the companies that they are excited about and you want to get to know those. So it's very symbiotic. I couldn't agree more wholeheartedly. I always say it, and I think you put it in the right way when you said that we angel LP invest because, of course, it's always nice to get a big ticket. But what you really want from someone like you is the signal value of having been picked by someone who knows their game as well as you do.

43:27And that is exactly what you're in the position to be able to do as an accomplished GP or firm. You know what you're looking for because you're basically looking at someone who you would otherwise hire. So in that sense, it's the perfect high signal, low ticket investor in my view for an emerging manager to go after and try and secure as one of your early LPs. So just a big shout out to all of you at LocalGlobe for Latitude for building this and being outspoken about doing it. And a big recommendation for anyone listening in who are thinking about building a fund, try and get a senior GP on as soon as you can as an LP.

44:21I'd love to ask you about how do you think about the role of mentors in Venture? How do you practice it yourself? What are your guiding principles when it comes to helping the next generation of Venture growing up? I can maybe do this section where you're asking me to do a call out of someone because I think I wanted to call out one of my main mentors, which is Bruce Golden at Excel. I was fortunate enough to join a board where he is the chair. The company is called Moshi. It's a children's wellness product. You maybe use it because you have kids. They're not good enough at English. And I went to their website when I saw it in your notes.

45:04And then I thought, I'm going to check that out. And then I thought, fuck, I'm sure it's not in English. So I didn't dive further, but I thought I'd actually check it out. Well, I don't think it matters. Well, maybe it does matter. Yes, I mean, we listen. It does because there's quite a bit of stories in there. And my son is actually a bit maybe on the spectrum of ADHD, kind of like maybe someone else in his family. uh so for that reason it would be super cool to have something that would help him relax and yeah have a tutor he's a mish on our team mish on our team listens to the stories he thinks that they're great um yeah anyway uh i guess just a bit of context on bruce you know he's a phenomenal investor he's been with excel for many years he was in london he's now based in san francisco He has huge conviction in this children's wellness space.

45:58He's typically a B2B SaaS investor, but this is obviously a consumer subscription business. It has been through many pivots. It started as Mind Candy. It then became Moshi. There have been leadership changes, you know, all of the ups and downs of company building. And I think what I learned from Bruce was what it means to have conviction. like very, very long-term thinking. He is a phenomenal communicator. His clarity of thought is unparalleled. And I think, you know, how he acted in very tricky times, both, you know, moving quickly as well as slowly when needed, and how he managed these situations with such grace, with humility and with, yeah, just huge empathy for the people that we're working with, I think for me was a masterclass in how to be a great investor.

47:03And so what I think about is, you know, I would hope that at some point in time, I can repay my debt of gratitude that I have for Bruce for someone else. And that I hope at someday I will have the experience to be able to share what I have learned and to have other investors work alongside me in the same way that I was able to work alongside Bruce. And so I guess, yeah, how do I think about that? I think mentorship is hugely important. And I think that you learn so much from co-investing with others and from working through challenges together. And I think that those are the moments that you have the deep connections with co-investors where you really understand the extent to which you are aligned and how you work through challenges, like I've mentioned.

47:56But yeah, there are in particular, I think there are women that I spend time with and want to see how I can help in any what way, whether it's thinking through challenges like this company is going through founder challenges or this founder breakup what what do i know about that i've actually now seen a couple of those happen specific challenges whether it's um whatever it might be making yourself available i think is the way to yeah it's it's it's the way to pass on that baton and what you've learned so far

48:38you mentioned women in venture there we're seeing quite a few pieces talking about an exodus of women from venture there's of course multiple reflections and and thoughts around why why that is some of it being that well we're seeing a weeding out of anyone who doesn't have a very, very strong track record because funds are calling. And if you haven't been a venture for a long time, and it's unfortunately a newer trend that we would have more diversity in the industry. So there is some natural, harder effect from the fact that we have funds downsizing now. And then I think there's also some that describe it as that there are many women that have fallen out of love with venture from having gone through the period that we have been in after tech reset and then seen what might be called the uglier side of venture.

49:38And then all of a sudden, everyone aren't as nice friends as they used to be. I'd love to ask you how you think about this exodus. Do you see it as real? I think there are always going to be people who are leaving for whatever reason. I guess that the question is if it's systemic. I do think that it's harder for women in venture. And I think the stats that, you know, the European, the state of European tech report shows, shows that it's not improving for women. It's not improving for black people. And so I think you have to have real staying power and real conviction that this is something that you want to do.

50:23And so I think that is the true challenge for individuals. From our perspective, I think the way that we think about, I mean, hiring for our team, for example, or even what we recommend for our companies is like for short lists. So top of the funnel, we want to see, you know, 50 % women, 20 % black. And yes, you can run a fair process after that. I mean, and I think this is for us as a fund that are expanding, we're not contracting. And we have deep conviction in the European opportunity. So I think, I mean, it's really difficult for me to say what it's like at other funds or the individual reasons why people are leaving.

51:10But I think that's how I think about it, that the diverse teams, they make better decisions. They perform better. They communicate better. we as a fund are really committed yet to ensuring that those that those beliefs and that our team is a representation of the future that we want to see and that's I mean that's also why why Saul started Newton I'm a Kauffman fellow and I was really really proud to be a Kauffman fellow class 18 it was very different to how the classes are structured today we had 20 people in the class but I think we were nearly 50 % women. But at the same time, Kauffman Fellowship costs, I think 80 ,000 pounds a year at the time.

51:58I was so lucky. Universal Music paid for my Kauffman Fellowship. They said, you think you have this great idea? Well, we need to help support you. I was super lucky. Like, I guess Newton Fellowship is obviously much more accessible. On the other hand, there are more people. It's bigger classes. but again, it's enabling, you know, giving people a taste. Like, is this something for me? Is this something that I'm excited about? Is this something where I think I can make a difference? Whether it's as an investor, as a founder, as a whatever it might be, just giving you a taste of the innovation economy.

52:37And so I think those two aspects are, I guess, maybe more my personal experience and then how we think about it on a macro basis. Now, Julia, I want to ask you to go into your three biggest learnings from the last 10 years in your life. I know this is such a tough question. Yes, we're all about the tough questions here. I really had to think hard about this. But for me, I would say, one, values. And I guess also to caveat, 10 years ago, I had not yet had my daughter. I was still working at Universal Music. And so really, the last 10 years, I think, have been really important from a growth perspective for me.

53:26But the things that I have learned over the past 10 years are, one, the importance of articulating your values and using them as a way to govern decision making. You can obviously have your personal values, but you also need to understand your firm's values. And I think the fact that we have very clearly articulated values, which are around conviction, empathy, partnership, openness, trust, and equity, being able to use those in situations that are challenging means that you can ground the decision in values and you can really explain why you want to do something versus not. So that's one. The second one is about the ability to turn poison into medicine.

54:17And I think for me, this means that your biggest challenges will become your most important teachers, and winning over these challenges will be the most rewarding progress you can make. I feel like I am able to point to countless of, not countless examples, but there are many examples where I have seen this happen. And so I really take that with me every day. And then the third thing, which is more investor specific, but it's about actually having conviction in something feels uncomfortable for me. Other people, or I guess what you may see from the outside is that, you know, VC being quite an alpha game where you have conviction and it's all rah, rah, rah.

55:08Well, actually, for me, it's rather the opposite. like you can work and you can build conviction in something. You can work with your team. You can work through all of the different aspects to be able to make a case. But the largest outcomes will come from those bets where there wasn't consensus or where you may have been out on a limb. And for me, that always feels scary because you are obviously deploying capital and it feels scary. So those are my three big learnings. Yeah, but that's a very, very good point because having conviction sounds like a nice thing, right? But since we're also in a non-consensus industry, that means that you're having probably conviction against others.

55:57And that means your chips are on the table and someone else is saying we shouldn't put them there. my heart's beating my mouth is dry like yes that's what it feels like so now i want to ask you for your vc specific learnings for the last 10 years because i am sure you have a bunch okay so i think my vc specific learnings one i think founder splits are very common uh they're not a death sentence um so if you are new to the game please don't be too alarmed i think the founders who make tough decisions quickly and fairly, they move faster. Do what's best for the company are my learnings on that point.

56:43Don't optimize for valuation. Obviously, optimize for the right partner and raising at a high valuation doesn't equate to long-term success. And I think we're obviously starting to see that now in particular. I would say in terms of some of the healthcare specific learnings is that the pre-seed and seed company building blocks are actually similar across sectors, but healthcare companies also need to consider regulation and healthcare go to market much earlier. And then I would say that trust and agency are absolutely critical in the founder investor relationship. And I guess what I have learned is that if there is trust, then it means that you can come and you can share problems like founder splits much earlier on before it becomes a 999 issue or a 999 call.

57:37And agency just means that it's the founder's company. And obviously that we as investors can provide advice, we can provide thoughts, we can provide recommendations, but ultimately it's the founder's decision. And again, to the point of trust, if there's no trust, then there's no point in making a recommendation because the founder won't listen. And then I think discipline leads to freedom. I think this is just something, I mean, it's not from the last 10 years. I think that's something that I have thought about for a long time. But it's no surprise that some of the best founders I work with are, they have either deep religious faith, they're ex-athletes, or have worked in the military or ex-military.

58:29So those are some of my learnings. And those were incredibly interesting. And we should have done an episode just on those. But for now, let's get into the quickfire section. And now, the quickfire.

58:50Julia, first question. What advice would you give to your own 10-year younger self? Yes. Okay, so my own 10-year younger self, I would say this. Julia, there is literally no challenge you cannot overcome. You will have many disagreements and struggles in relationships. use your courage, your wisdom and your voice to overcome them. Two, it's kind to be clear. A quick and friendly no doesn't have to be an art form. And three, it doesn't have to be perfect. You just have to start. And also the word yet will change your life. Lastly, you can be yourself and still win. What are your top tips for emerging VCs across Europe who are fundraising?

59:39So again, love working with emerging managers, hugely important part of the ecosystem. I would say, like all of us, one, continue developing your edge. Make sure that you see everything in your chosen thematic focus. Again, companies or emerging managers like Carl at Black Sea, Jamie at Crater Fund, Chris at Atria do this really well. Also communicate your edge to founders. Chris gets into really good companies because he has a very strong value proposition and really helps founders with pharma go to market, which is something that many founders want. Two, I would say track your investments really closely and write great memos.

1:00:21Ramsey at No Label is best in class at this. And then I would say broaden who you would target for investment. It's exactly as we spoke about earlier, consider raising from angels, family offices, VCs who are aligned with your theme. And I would point to the episode of Gloria Barline. She, I thought her, it was phenomenal listening to her. So yeah, the playbook is there. So I would say, yeah, develop your relationships with follow on investors. I think this is probably a no brainer. But yeah, people like Carmen and Cocoa obviously do this phenomenally well. Also Izzy at Outsized also does this really really well.

1:00:59And what's the most counterintuitive thing you've learned in venture? I never thought it would have mattered so much to be based in Summerstown. So the decision to base ourselves here in a building owned by the council really has become our superpower. And yeah, and I couldn't really imagine being based anywhere else.

1:01:25I think we're back to, is it Scotland? PPP, product positioning and price or something like that. I think at least there's something about positioning being the most important thing in the world. So that's good fun. So now, Julia, before we stop, I want to ask you to just share with us a long held belief that you have that most around you don't believe. I think this is a great question. And when I think about it, I would say that the venture community has broadly failed to increase living standards. If I again come back to the people of Summers Town, like what has really been the impact of the innovation economy of the people who live here?

1:02:12And therefore, people across Europe and across the world. Again, Summers Town, highest proportion of child poverty in the borough. Are the beneficiaries of the innovation economy still a very elite few? I think in terms of goods and services, of course, there have been really impactful companies and services, products and services that are now available. But have they really, have they really enabled social mobility? I am less certain that they have enabled the kind of social mobility that we saw as a result of some of the electric and household appliances of the Industrial Revolution. And then I would say, I guess, you know, on this point that, you know, we as a fund, I wouldn't say it was an experiment, but we took the stance that we wanted to basically create and start Phoenix Court Works, which is the foundation, which then takes 10 % of profits from our management company, 2 % of carry across all of our funds.

1:03:16and we basically deploy that and support social initiatives across our local community. I mean, for me, that's been really important because its value is aligned with me. But I'm just wondering, like, how do we do that at scale? That's an incredibly important question for all of us to ask ourselves with everything that we do. Julia, you have been amazing. You made us go over time, or maybe I did. I don't know. But thanks so much for doing so. Thank you so much for joining us, everyone listening in. I really hope you enjoyed this conversation and you'll be sharing it with your friends, that you'll drop us a review on wherever you listen to the pod and also go on EU.VC, subscribe and tell everyone about my Papa Santa over here, who is joining us for a couple of weeks of interviews.

1:04:05Thank you, everyone.

1:04:09Tear down this wall. It's more than just an alliance. This is a union of values. United and determined, we can serve as a model for other regions of the world. The nature of a problem requires a European response. Europe is a story of new beginnings. Let's start acting.

From the publisher
Today, we have Julia Hawkins with us. Julia is a General Partner at Phoenix Court, a $1.5bn AUM EMEA multi-stage tech investor, backing the most ambitious founders on their journey from seed through to public markets and beyond over the last two decades.

LocalGlobe is the pre-seed and seed fund investing out of Phoenix Court’s Fund 12 with an established portfolio of over 200 companies with notable investments including At-Bay, Motorway, Zego and Improbable. At Phoenix Court, Julia focuses on health and hard tech and led investments into AccuRx, Oxford Nanopore, Vaccitech, and more recently Spore Bio and Early Health.

Go to eu.vc for our core learnings and the full video interview 👀

Chapters:00:00:00 Welcome to the European VC Podcast with Julia Hawkins
00:00:26 Diving Deep into Phoenix Court and Multi-Stage Investing
00:04:22 Julia Hawkins' Journey into Venture Capital
00:15:44 The Impact of Personal Experiences on Professional Paths
00:18:27 Exploring the Future of Hard Tech in Europe
00:34:09 Exploring Healthcare Innovations and Community Impact
00:34:33 The Unique Approach of Local Globe in Healthcare Investments
00:35:25 Building Relationships and Community in the Healthcare Sector
00:44:21 Mentorship and Diversity in Venture Capital
00:52:47 Advice for Emerging VCs

More from EUVC

All 626 episodes
EUVC #286 Julia Hawkins, GP at LocalGlobe & Phoenix Court on building a healthcare franchise in a generalist fundEUVC · 1 h 5 min
Listen in VO